|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Endoscopic ultrasonography guided biliary drainage: Summary of consortium meeting, May 7^(th) , 2011, Chicago显示文摘Endoscopic retrograde cholangiopancreatography (ERCP) has become the preferred procedure for biliary or pancreatic drainage in various pancreatico-biliary disorders. With a success rate of more than 90%, ERCP may not achieve biliary or pancreatic drainage in cases with altered anatomy or with tumors obstructing access to the duodenum. In the past those failures were typically managed exclusively by percutaneous approaches by interventional radiologists or surgical intervention. The morbidity associated was significant especially in those patients with advanced malignancy, seeking minimally invasive interventions and improved quality of life. With the advent of biliary drainage via endoscopic ultrasound (EUS) guidance, EUS guided biliary drainage has been used more frequently within the last decade in different countries. As with any novel advanced endoscopic procedure that encompasses various approaches, advanced endoscopists all over the world have innovated and adopted diverse EUS guided biliary and pancreatic drainage techniques. This diversity has resulted in variations and improvements in EUS Guided biliary and pancreatic drainage; and over the years has led to an extensive nomenclature. The diversity of techniques, nomenclature and recent progress in our intrumentation has led to a dedicated meeting on May 7 th , 2011 during Digestive Disease Week 2011. More than 40 advanced endoscopists from United States, Brazil, Mexico, Venezuela, Colombia, Italy, France, Austria, Germany, Spain, Japan, China, South Korea and India attended this pivotal meeting. The meeting covered improved EUS guided biliary access and drainage procedures, terminology, nomenclature, training and credentialing; as well as emerging devices for EUS guided biliary drainage. This paper summarizes the meeting's agenda and the conclusions generated by the creation of this consortium group. | Michel Kahaleh Everson LA Artifon Manuel Perez-Miranda Kapil Gupta Takao Itoi Kenneth F Binmoeller California Pacific Medical Center San Francisco CA 94115 United States Marc Giovannini | 2013 | World Journal of Gastroenterology2013，19，9： | 15 |
| 2 | Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics显示文摘Multiple myeloma is a hematological malignancy inwhich clonal plasma cells proliferate and accumulate within the bone marrow. The presence of osteolytic le-sions due to increased osteoclast(OC) activity and sup-pressed osteoblast(OB) function is characteristic of the disease. The bone marrow mesenchymal stromal cells(MSCs) play a critical role in multiple myeloma patho-physiology, greatly promoting the growth, survival, drug resistance and migration of myeloma cells. Here, we specifically discuss on the relative contribution of MSCs to the pathophysiology of osteolytic lesions in light of the current knowledge of the biology of my-eloma bone disease(MBD), together with the reported genomic, functional and gene expression differences between MSCs derived from myeloma patients(pMSCs) and their healthy counterparts(dMSCs). Being MSCs the progenitors of OBs, pMSCs primarily contribute to the pathogenesis of MBD because of their reduced osteogenic potential consequence of multiple OB inhibi-tory factors and direct interactions with myeloma cells in the bone marrow. Importantly, pMSCs also readily contribute to MBD by promoting OC formation and ac-tivity at various levels(i.e., increasing RANKL to OPG expression, augmenting secretion of activin A, uncou-pling ephrinB2-EphB4 signaling, and through augment-ed production of Wnt5a), thus further contributing to OB/OC uncoupling in osteolytic lesions. In this review, we also look over main signaling pathways involved in the osteogenic differentiation of MSCs and/or OB activity, highlighting amenable therapeutic targets; in parallel, the reported activity of bone-anabolic agents(at preclinical or clinical stage) targeting those signaling pathways is commented. | Antonio Garcia-Gomez Fermin Sanchez-Guijo M Consuelo del Caizo Jesus F San Miguel Mercedes Garayoa | 2014 | World Journal of Stem Cells2014，6，3： | 5 |
| 3 | Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation显示文摘Antibody-mediated rejection(AMR) caused by donorspecific anti-human leukocyte antigen antibodies(DSA) is widely accepted to be a risk factor for decreased graft survival after kidney transplantation. This entity also plays a pathogenic role in other solid organ transplants as it appears to be an increasingly common cause of heart graft dysfunction and an emerging issue in lung transplantation. In contrast, the liver appears relatively resistant to DSA-mediated injury. This 'immune-tolerance' liver property has been sustained by a low rate of liver graft loss in patients with preformed DSA and by the intrinsic liver characteristics that favor the absorption and elimination of DSA; however, alloantibody-mediated adverse consequences are increasingly being recognized, and several cases of acute AMR after ABO-compatible liver transplant(LT) have been reported. Furthermore, the availability of new solid-phase assays, allowing the detection of low titers of DSA and the refinement of objective diagnostic criteria for AMR in solid organ transplants and particularly in LT, have improved the recognition and management of this entity. A cost-effective strategy of DSA monitoring, avoidance of class Ⅱ human leukocyte antigen mismatching, judicious immunosuppression attached to a higher level of clinical suspicion of AMR, particularly in cases unresponsive to conventional antirejection therapy, can allow a rational approach to this threat. | Antonio Cuadrado David San Segundo Marcos López-Hoyos Javier Crespo Emilio Fábrega | 2015 | World Journal of Gastroenterology2015，21，39： | 5 |
| 4 | Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results显示文摘这份报告在活跃监视上在 T 缺乏的人的一个队与 T 治疗介绍我们的经验(作为) 为 Gleason 3 + 3 并且 Gleason 3 + 4 前列腺癌症(PCa ) 。回顾的图表评论与 T 缺乏识别了 28 个人经历 T 治疗(T 组) 至少 6 个月了当时在上至于 PCa。96 个人在上的一个比较组至于有未经治疗的 T 缺乏的 PCa (别组织) 在一样的机构被识别。同样协议跟随了修改爱泼斯坦标准和有小量的 Gleason 3 + 的一个单个核心的人的允许的包括 4 PCa。吝啬的年龄是 59.5 和 61.3 年,并且意味着后续是为 T 的 38.9 和 42.4 个月并且不分别地组织。在 T 组的所有 28 个人, 3 (10.7%) 人们在格利森分数开发了增加当时在上作为。22,在 T 的人与 Gleason 3 + 组织 3 疾病, 7 (31.8%) 人们包括开发了 Gleason 3 + 的 3 个人(13.6%) 开发了活体检视前进 4 PCa。有 Gleason 3 + 的 6 个人在基线的 4 疾病, 2 (33.3%) 人们在肿瘤体积开发了增加,并且任何一个都没发展在 Gleason 3 + 以外升级 4。所有 96 个人在别组织有的 Gleason 3 + 在基线的 3 疾病并且,(44.7%) 43 开发了活体检视前进,包括有升级到 Gleason 7 的 9 个人(9.38%)(3 + 4 ) 。活体检视前进率为组和历史的控制是类似的。在人在上的活体检视前进作为在 3 年由 T 治疗显得未受影响。在 T 缺乏的人在上的 T 治疗的未来的控制安慰剂的试用作为应该被认为给对待的人经验丰富的征兆的好处。 | Ravi Kacker Mariam Hult Ignacio F San Francisco William P Conners Pablo A Rojas William C Dewolf Abraham Morgentaler | 2016 | Asian Journal of Andrology2016，18，1： | 2 |
| 5 | Pre-oxidation of an extremely polluted industrial wastewater by the Fenton’s reagent显示文摘 | Nora San Sebastián Mart??nez Josep F??guls Fernández Xavier Font Segura Antoni Sánchez Ferrer | 2003 | Journal of Hazardous Materials2003，，3： | 2 |
| 6 | Genetic relationships among Spanish sheep using microsatellites显示文摘 | Arranz J J Bayon Y San Primitivo F | 1998 | Animal Genetics1998，29，6： | 2 |
| 7 | Hepatic resection in localized Caroli disease显示文摘 | Espinoza R San Martin S Court F | 2003 | Rev Med Chil2003，131，2： | 1 |
| 8 | Reboxetine ad-junct for partial or nonresponders to antidepressant treat-ment显示文摘 | Rubio G San L Lapez-Mu oz F | 2004 | J Affect Disord2004，81，1： | 1 |
| 9 | The spatial distribution of soils across Europe : A fractal approach 显示文摘 | Ibmez J J Prrez-G6mez R San Jos6 F | 2009 | Ecological Com- plexity2009，6，： | 1 |
| 10 | Yield, composition and rheelogical characteristics of cheddar cheese made with high pressure processed milk显示文摘 | San Mart N-Gonz Lez M F Rodr Guez J J Gurram S | 2007 | LWT - Food Science and Technology2007，40，4： | 1 |
| 11 | Epidemiological survey regarding pigmentation problem in yellow label chicken:identification of the principal risk factors on 178 farms in the South West of France显示文摘 | Sans P Horst F | 2000 | Science and Techniques Avicoles2000，33，： | 1 |
| 12 | Simulation of the seismic response of sedimeutary basins with vertical constant-gradient velocity for incident SH-waves显示文摘 | Luzon F Ramire Z L San chez-Sesma F J | 2004 | Pure and Applied Geophysics2004，161，7： | 1 |
| 13 | Evaluation of total oxidative stress parameters in patients with nasal polyps显示文摘 | Bozkus F San I Ulas T | 2013 | Acta Otorhinolaryngol Ital2013，33，4： | 1 |
| 14 | Effects of high energy milling on some functional properties of jicama starch ( Pachyrrhizus erosus L Urban) and cassava starch (Manihot esculenta Crantz ) 显示文摘 | Marttnez-Bustos F Lepez-Soto M San Martin-Martinez E | 2007 | Journal of Food Engineering2007，78，4： | 1 |
| 15 | The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection 显示文摘 | Jean O Ung Ignacio F San Francisco | 2003 | J Urol2003，169，： | 1 |
| 16 | Nasal polyp diseases in allergic and nonallergic patients and ster- oid therapy显示文摘 | ALATAS N BABA F SAN I | 2006 | Otolaryngol Head Neck Surg2006，135，： | 1 |
| 17 | Comparison of protein markers and microsatellites in differentiation of cattle populations显示文摘 | Bayon Y San Primitivo F | 1996 | Anim Genet1996，27，5： | 1 |
| 18 | 显示文摘 | PichelinMB RobertJ F Sans J L | 2006 | Applied Surface Science2006，253，2： | 1 |
| 19 | Pituitary apoplexy: retrospective study of 9 patients with hypophyseal adenoma显示文摘 | Carral San Laureano F Gavilan Villarejo I Olveira Fuster G | 2001 | An Med Interna2001，18，11： | 1 |
| 20 | MIMO radar ambiguity functions 显示文摘 | San Antonio G Fuhrmann D R and Robey F C | 2007 | IEEE Journal of Selected Topics in Signal Processing2007，1，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员